default author photo

Michael F. Berger

Memorial Sloan Kettering Cancer Center - Department of Pathology

New York, NY

United States

SCHOLARLY PAPERS

2

DOWNLOADS

189

TOTAL CITATIONS

1

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Number of pages: 51 Posted: 17 Dec 2019
Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Sabrina Arena, Benedetta Mussolin, Ram Kannan, Neil Vasan, Alexander N. Gorelick, Michael F. Berger, Yi Liao, Uwe Rix, Alberto Bardelli, Jacklyn Hechtman, Elisa de Stanchina, David M. Hyman, Chandra Verma, Andrea Ventura, Alexander Drilon and Maurizio Scaltriti
Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Cancer Biology and Genetics Program, Agency for Science, Technology and Research (A*STAR) - Bioinformatics Institute, Memorial Sloan Kettering Cancer Center - Department of Medicine, Memorial Sloan Kettering Cancer Center - Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, University of Torino - Department of Oncology, FPO-IRCCS - Candiolo Cancer Institute, Memorial Sloan Kettering Cancer Center - Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute - Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute - Department of Drug Discovery, University of Torino - Department of Oncology, Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center - Department of Medicine, Agency for Science, Technology and Research (A*STAR) - Bioinformatics Institute, Memorial Sloan Kettering Cancer Center - Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center - Department of Medicine and Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program
Downloads 122 (588,531)

Abstract:

Loading...

drug resistance, tyrosine kinase inhibitors, cancer, signaling

2.

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictor of Survival and Response to Therapy in Patients Treated with Immune Checkpoint Inhibitors

Number of pages: 37 Posted: 23 Jul 2020
Cristina Valero, Mark Lee, Douglas Hoen, Kate Weiss, Daniel Kelly, Prasad S. Adusumilli, Paul K. Paik, George Plitas, Marc Ladanyi, Michael A. Postow, Charlotte E. Ariyan, Alexander N. Shoushtari, Vinod P. Balachandran, Ari Hakimi, Aimee M. Crago, Kara C. Long Roche, J. Joshua Smith, Ian Ganly, Richard J. Wong, Snehal G. Patel, Jatin P. Shah, Nancy Y. Lee, Nadeem Riaz, Jingming Wang, Ahmet Zehir, Michael F. Berger, Timothy A. Chan, Venkatraman E Seshan and Luc Morris
Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Information Systems, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Medicine, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Department of Medicine, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Medicine, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Surgery, Memorial Sloan Kettering Cancer Center - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics and Memorial Sloan Kettering Cancer Center - Department of Surgery
Downloads 67 (899,324)
Citation 1

Abstract:

Loading...

Immune Checkpoint Inhibitors; Immunotherapy; Neutrophil-to-Lymphocyte Ratio; Biomarkers